Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Hydralazine
Drug ID BADD_D01081
Description Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed.[A186841] Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure.[A186820,L8782,L8785] Hydralazine is no longer a first line therapy for these indications since the development of newer antihypertensive medications.[T691] Hydralazine hydrochloride was FDA approved on 15 January 1953.[L8779]
Indications and Usage For the treatment of essential hypertension, alone or as an adjunct. Also for the management of severe hypertension when the drug cannot be given orally or when blood pressure must be lowered immediately, congestive heart failure (in combination with cardiac glycosides and diuretics and/or with isosorbide dinitrate), and hypertension secondary to pre-eclampsia/eclampsia.
Marketing Status Prescription; Discontinued
ATC Code C02DB02
DrugBank ID DB01275
KEGG ID D08044
MeSH ID D006830
PubChem ID 3637
TTD Drug ID D0K1XK
NDC Product Code Not Available
Synonyms Hydralazine | Hydrallazin | Hydrazinophthalazine | Apressin | Nepresol | Hydralazine mono-Hydrochloride | Hydralazine mono Hydrochloride | mono-Hydrochloride, Hydralazine | Apressoline | Apresoline | Hydralazine Hydrochloride | Hydrochloride, Hydralazine
Chemical Information
Molecular Formula C8H8N4
CAS Registry Number 86-54-4
SMILES C1=CC=C2C(=C1)C=NN=C2NN
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.0250.000663%
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.0010.000994%Not Available
Glomerulonephritis10.02.01.006; 20.05.01.0010.003976%Not Available
Glomerulonephritis proliferative20.05.01.0080.002485%Not Available
Glomerulonephritis rapidly progressive20.05.01.004; 10.04.04.0080.005301%Not Available
Granuloma skin23.03.15.0020.000331%Not Available
Haematuria24.07.01.047; 20.02.01.0060.000497%
Haemoglobin decreased13.01.05.003--Not Available
Haemolytic anaemia01.06.03.002--Not Available
Haemoptysis24.07.01.006; 22.02.03.004; 02.01.02.0060.000828%Not Available
Hallucination19.10.02.002--
Headache17.14.01.001--
Heart rate increased13.14.04.0020.000497%Not Available
Hepatic failure09.01.03.0020.000086%
Hepatic function abnormal09.01.02.001--Not Available
Hepatic necrosis09.01.07.0020.000130%
Hepatitis09.01.07.0040.000331%Not Available
Hepatitis cholestatic09.01.01.0020.000331%Not Available
Hepatomegaly09.01.05.001--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.0280.000497%
Hypersensitivity10.01.03.003--
Hypersensitivity vasculitis10.02.02.017; 01.01.04.008; 24.05.02.012; 23.06.02.0050.000663%Not Available
Hypertension24.08.02.0010.000994%
Hypertensive crisis24.08.01.0010.000331%Not Available
Hypoaesthesia17.02.06.023--Not Available
Hypotension24.06.03.0020.004141%
Hypoxia22.02.02.0030.000828%
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 7 Pages